Korea United Pharm. Inc.
Quick facts
Marketed products
- Cefecin Tab.
- Omnicef Cap. · Infectious Disease
Omnicef (cefdinir) is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Phase 3 pipeline
- KALOMIN™ Tab. · Electrolyte/Metabolic Disorders
KALOMIN is a potassium supplement that replaces depleted electrolytes to restore normal serum potassium levels. - UI05MSP015CT · Diabetes
This drug is a small molecule that targets the SGLT2 receptor. - Umckamin syrup · Respiratory / Immunology
Umckamin is an herbal extract that enhances immune function and reduces inflammation to help the body fight respiratory infections.
Phase 2 pipeline
Phase 1 pipeline
- administration of UI018
- administration of UI058
- administration of UI068
- administration of UIC202004
- administration of UIC202205, UIC202206
- Anplag · Other
- UI009
- UI03SPG300CT
- UI059
- UI15AML055MT
- UIC201602 and co-administration of UIC201601 and UIC201602
- UIC202005
- UIC202201
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Korea United Pharm. Inc.
What are Korea United Pharm. Inc.'s marketed drugs?
Top marketed products include Cefecin Tab., Omnicef Cap..
What is Korea United Pharm. Inc.'s pipeline?
Korea United Pharm. Inc. has 3 drugs in Phase 3, 1 in Phase 2, 13 in Phase 1. Late-stage candidates include KALOMIN™ Tab., UI05MSP015CT, Umckamin syrup.
Related
- Cefecin Tab.
- Omnicef Cap. · Infectious Disease
- Sector hub: All tracked pharma companies